Next Article in Journal
Towards a More Comprehensive Approach for a Total Economic Assessment of Vaccines?
Previous Article in Journal
Use and Cost Comparison of Clobazam to Other Antiepileptic Drugs for Treatment of Lennox-Gastaut Syndrome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 5
Issue 1
10.1080/20016689.2017.1335161
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Direct Cost Analysis of the Second Year Post-allogeneic Hematopoietic Stem Cell Transplantation in the Bone Marrow Transplant Centre of Tunisia

by
Myriam Razgallah Khrouf
1,3,
Leila Achour
1,3,*,
Asma Thabti
1,3,
Mohamed Ali Soussi
1,3,
Nour Abdejelil
2,4,
Olfa Lazreg
1,
Chema Drira
1,3,
Aida Zahaf
1,
Saloua Ladab
2,4 and
Tarek Ben Othman
2,4
1
Service Pharmacie, Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia
2
Service de Greffe et Hématologie, Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia
3
Faculté de Pharmacie de Monastir, Tunisie
4
Université de Tunis El Manar Faculté de Médecine de Tunis, Tunisie
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1335161; https://doi.org/10.1080/20016689.2017.1335161
Submission received: 8 March 2017 / Revised: 8 March 2017 / Accepted: 19 May 2017 / Published: 15 June 2017

Abstract

Background: Hematopoietic stem cell transplantation (HSCT) is a medically complicated therapy with a long recovery time. In Tunisia, the National Health Insurance Fund (CNAM) covers only the first year post-transplantation, after which the costs are borne by the hospital. Objective: Describe complications that can occur during the second year post-allogeneic HSCT and calculate direct costs in different groups of patients. Methods: In this pharmacoeconomic study, medical records of the second year post-allogeneic HSCT were collected. Studied variables included frequent observed complications and medical and non-medical direct costs. Results: The average total direct cost in the population during the second year post-transplantation was $11,571, 97% of which represents direct medical costs Drugs accounted for the largest share (80%) of total direct costs, dominated by the cost of antifungals (52%) and antivirals (26%) drug . Cytomegalovirus status was seen in 9.3% of patients and was associated with a seven-fold increase in direct costs (p < 0.001).​​ In patients who developed chronic GVHD, the average direct cost was three times higher than for those who did not (p = 0.032). Conclusion: Given the importance of direct costs in the post-transplantation period a review of the hospital financing mechanism and a new convention with the CNAM is crucial.​​
Keywords: Allogeneic stem cell transplantation; complications; cost; pharmacoeconomic Allogeneic stem cell transplantation; complications; cost; pharmacoeconomic

Share and Cite

MDPI and ACS Style

Razgallah Khrouf, M.; Achour, L.; Thabti, A.; Soussi, M.A.; Abdejelil, N.; Lazreg, O.; Drira, C.; Zahaf, A.; Ladab, S.; Ben Othman, T. Direct Cost Analysis of the Second Year Post-allogeneic Hematopoietic Stem Cell Transplantation in the Bone Marrow Transplant Centre of Tunisia. J. Mark. Access Health Policy 2017, 5, 1335161. https://doi.org/10.1080/20016689.2017.1335161

AMA Style

Razgallah Khrouf M, Achour L, Thabti A, Soussi MA, Abdejelil N, Lazreg O, Drira C, Zahaf A, Ladab S, Ben Othman T. Direct Cost Analysis of the Second Year Post-allogeneic Hematopoietic Stem Cell Transplantation in the Bone Marrow Transplant Centre of Tunisia. Journal of Market Access & Health Policy. 2017; 5(1):1335161. https://doi.org/10.1080/20016689.2017.1335161

Chicago/Turabian Style

Razgallah Khrouf, Myriam, Leila Achour, Asma Thabti, Mohamed Ali Soussi, Nour Abdejelil, Olfa Lazreg, Chema Drira, Aida Zahaf, Saloua Ladab, and Tarek Ben Othman. 2017. "Direct Cost Analysis of the Second Year Post-allogeneic Hematopoietic Stem Cell Transplantation in the Bone Marrow Transplant Centre of Tunisia" Journal of Market Access & Health Policy 5, no. 1: 1335161. https://doi.org/10.1080/20016689.2017.1335161

APA Style

Razgallah Khrouf, M., Achour, L., Thabti, A., Soussi, M. A., Abdejelil, N., Lazreg, O., Drira, C., Zahaf, A., Ladab, S., & Ben Othman, T. (2017). Direct Cost Analysis of the Second Year Post-allogeneic Hematopoietic Stem Cell Transplantation in the Bone Marrow Transplant Centre of Tunisia. Journal of Market Access & Health Policy, 5(1), 1335161. https://doi.org/10.1080/20016689.2017.1335161

Article Metrics

Back to TopTop